Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES-3000 plus ASTX727 for high-risk myelodysplastic syndrome and low-blast acute myeloid leukemia
ACTRN12621001713886Phase 2Active, not recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jun 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tetrandrine and inqovi in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Dose-limiting toxicities of ES-3000 and determination of recommended phase 2 dose, Incidence and severity of adverse events and 1 more. Started Jun 2023; status: active, not recruiting.
02
Drugs
tetrandrineinqovi
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12621001713886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001713886.